Ketamine: A New Dawn for Treatment-Resistant Depression in Singapore
SINGAPORE – For patients struggling with treatment-resistant depression, hope has arrived in the form of a once-unconventional treatment: ketamine. What was once primarily known as an anesthetic for animals and a recreational drug has emerged as a groundbreaking therapy, offering relief to individuals who haven’t responded to traditional antidepressants.
Over the past four years, the use of ketamine in Singapore has surged, with many psychiatrists witnessing remarkable results. Dr. Tania Lee, a prominent psychiatrist at the Centre for Psychological Services, shares, "I’ve seen a significant improvement in my patients who had previously exhausted all other treatment options. It truly is a game-changer.”
Clinical guidelines now frequently recommend Spravato, a ketamine-based nasal spray developed by Johnson & Johnson, for those battling treatment-resistant depression. The drug’s rapid effects, non-invasive administration, and proven efficacy have made it a favored choice among both professionals and patients.
One patient, who preferred to remain anonymous, shared her transformative experience. "After years of feeling trapped by depression, Spravato gave me back my life. It’s not a miracle cure, but it allowed me to regain control and start healing."
But the change in the medical landscape goes beyond just Spravato. At the Institute of Mental Health, intravenous ketamine is administered under strict medical supervision, offering a more affordable alternative for patients who qualify.
Dr. David Chen, head of the Ketamine Treatment Clinic at the Institute of Mental Health, emphasizes, “While Spravato offers a convenient solution for many, we strive to make effective ketamine treatment accessible to all those in need, regardless of their financial situation."
While the success stories are inspiring, the journey isn’t without challenges. The high cost of Spravato remains a significant barrier for many, with each session averaging $1,000. Limited insurance coverage further exacerbates the financial strain, prompting calls for more affordable options and broader access to treatment.
Despite these hurdles, the growing body of evidence supporting ketamine’s effectiveness in treating depression, coupled with the increasing availability of different treatment modalities, paves the way for a brighter future for individuals struggling with this debilitating illness.
As Dr. Lee aptly notes, "Ketamine is not a magic bullet, but it’s a powerful tool in our arsenal against depression. With ongoing research and continued efforts to address access and affordability, we can ensure that this life-changing treatment reaches everyone who needs it."
The post Controlled drug Ketamine a lifeline for patients with severe depression in Singapore appeared first on Archynewsy.